BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CD123 targeted CAR-NK cells readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CD123 targeted CAR-NK cells\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06690827-2853@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:CD123 targeted CAR-NK cells: Phase 1 readout est. (NCT06690827)
DESCRIPTION:CD123 targeted CAR-NK cells\, phase 1\, Acute Myeloid Leukemia.
 \nStudy: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refra
 ctory AML or BPDCN\nEstimated primary completion: 30 June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cd123-targeted-car-nk-cells#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0669082
 7
URL:https://assetmemo.bio/drug/cd123-targeted-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
